Ro 21-5104: structure given in first source; main metabolite of mefloquine [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
| ID Source | ID |
|---|---|
| PubMed CID | 169721 |
| CHEMBL ID | 1566286 |
| CHEBI ID | 171694 |
| SCHEMBL ID | 7075474 |
| MeSH ID | M0159698 |
| Synonym |
|---|
| CC-PMLSC-DMA-P115 , |
| CHEBI:171694 |
| 35853-50-0 |
| 2,8-bis-trifluoromethyl-4-quinoline carboxylic acid |
| 2,8-bis(triluoromethyl)quinoline-4-carboxylic acid |
| smr000209015 |
| MLS000889027 |
| SDCCGMLS-0091902.P001 |
| NCGC00142334-01 |
| mefloquine carboxylic acid |
| 2,8-bis(trifluoromethyl)quinoline-4-carboxylic acid |
| FT-0664331 |
| HMS2194A24 |
| unii-462l37ks1k |
| 4-quinolinecarboxylic acid, 2,8-bis(trifluoromethyl)- |
| ro 21-5104 |
| 2,8-bis(trifluoromethyl)-4-quinolinecarboxylic acid |
| ro-21-5104 |
| 462l37ks1k , |
| 2,8-mmq |
| carboxymefloquine |
| HMS3338K18 |
| AKOS022185218 |
| 2,8-bis-(trifluoromethyl)-quinoline-4-carboxylic acid |
| SCHEMBL7075474 |
| CHEMBL1566286 |
| cid_169721 |
| 2,8-bis(trifluoromethyl)cinchoninic acid |
| bdbm35452 |
| mfcd09840196 |
| DTXSID80189403 |
| 2,8-bis-(trifluoromethyl)-4-quinolinecarboxylic acid |
| 4-quinolinecarboxylic acid, 2,8-bis(trifluoromethyl)-ro 21-5104 |
| 2,8-bis(trifluromethyl)-4-quinolin carboxylic acid |
| 2,8-bistrifluoromethyl-4-quinoline carboxylic acid |
| DS-8811 |
| qjtjiqbszlfwfs-uhfffaoysa-m |
| 1,1-ferrocenedicarboxylicacid |
| Q27258890 |
| SB72187 |
| 2,8-bis(trifluoromethyl)quinoline-4-carboxylicacid |
| 2,8-bis(trifluromethyl)-4-quinolincarboxylic acid |
| CS-0365006 |
| Excerpt | Reference | Relevance |
|---|---|---|
| " This study determined the pharmacokinetic characteristics of the mefloquine stereoisomers and the metabolite carboxymefloquine (CMQ) when given as IPTp in pregnant women." | ( Population Pharmacokinetics of Mefloquine Intermittent Preventive Treatment for Malaria in Pregnancy in Gabon. Akerey-Diop, D; Basra, A; Geditz, M; Gonzalez, R; Hofmann, U; Kerb, R; Kremsner, PG; Lehr, T; Mackanga, JR; Matsiegui, PB; Menendez, C; Mombo-Ngoma, G; Ramharter, M; Schwab, M; Wojtyniak, JG; Würbel, H; Zoleko Manego, R, 2019) | 0.51 |
| Excerpt | Reference | Relevance |
|---|---|---|
| " In the split-dose group, mefloquine bioavailability was significantly increased by 5%." | ( Population Pharmacokinetics of Mefloquine Intermittent Preventive Treatment for Malaria in Pregnancy in Gabon. Akerey-Diop, D; Basra, A; Geditz, M; Gonzalez, R; Hofmann, U; Kerb, R; Kremsner, PG; Lehr, T; Mackanga, JR; Matsiegui, PB; Menendez, C; Mombo-Ngoma, G; Ramharter, M; Schwab, M; Wojtyniak, JG; Würbel, H; Zoleko Manego, R, 2019) | 0.51 |
| Excerpt | Relevance | Reference |
|---|---|---|
| " No special dosage adjustments have to be made in patients undergoing hemodialysis treatment to achieve concentrations in plasma similar to those in healthy volunteers." | ( Influence of hemodialysis on plasma concentration-time profiles of mefloquine in two patients with end-stage renal disease: a prophylactic drug monitoring study. Crevoisier, CA; Fischer, M; Graf, H; Joseph, I, 1995) | 0.29 |
| Class | Description |
|---|---|
| quinolines | A class of aromatic heterocyclic compounds each of which contains a benzene ring ortho fused to carbons 2 and 3 of a pyridine ring. |
| [compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] | |
| Protein | Taxonomy | Measurement | Average (µ) | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
|---|---|---|---|---|---|---|---|
| vitamin D3 receptor isoform VDRA | Homo sapiens (human) | Potency | 79.4328 | 0.3548 | 28.0659 | 89.1251 | AID504847 |
| geminin | Homo sapiens (human) | Potency | 8.1995 | 0.0046 | 11.3741 | 33.4983 | AID624296 |
| muscleblind-like protein 1 isoform 1 | Homo sapiens (human) | Potency | 79.4328 | 0.0041 | 9.9625 | 28.1838 | AID2675 |
| Guanine nucleotide-binding protein G | Homo sapiens (human) | Potency | 11.2202 | 1.9953 | 25.5327 | 50.1187 | AID624287 |
| [prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] | |||||||
| Process | via Protein(s) | Taxonomy |
|---|---|---|
| negative regulation of inflammatory response to antigenic stimulus | Guanine nucleotide-binding protein G | Homo sapiens (human) |
| renal water homeostasis | Guanine nucleotide-binding protein G | Homo sapiens (human) |
| G protein-coupled receptor signaling pathway | Guanine nucleotide-binding protein G | Homo sapiens (human) |
| regulation of insulin secretion | Guanine nucleotide-binding protein G | Homo sapiens (human) |
| cellular response to glucagon stimulus | Guanine nucleotide-binding protein G | Homo sapiens (human) |
| [Information is prepared from geneontology information from the June-17-2024 release] | ||
| Process | via Protein(s) | Taxonomy |
|---|---|---|
| G protein activity | Guanine nucleotide-binding protein G | Homo sapiens (human) |
| adenylate cyclase activator activity | Guanine nucleotide-binding protein G | Homo sapiens (human) |
| [Information is prepared from geneontology information from the June-17-2024 release] | ||
| Process | via Protein(s) | Taxonomy |
|---|---|---|
| plasma membrane | Guanine nucleotide-binding protein G | Homo sapiens (human) |
| [Information is prepared from geneontology information from the June-17-2024 release] | ||
| Assay ID | Title | Year | Journal | Article |
|---|---|---|---|---|
| AID504812 | Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign | 2010 | Endocrinology, Jul, Volume: 151, Issue:7 | A small molecule inverse agonist for the human thyroid-stimulating hormone receptor. |
| AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
| AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5 | Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
| AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1 | High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
| AID651635 | Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression | |||
| AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
| AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5 | Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
| AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1 | High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
| AID504810 | Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign | 2010 | Endocrinology, Jul, Volume: 151, Issue:7 | A small molecule inverse agonist for the human thyroid-stimulating hormone receptor. |
| AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
| AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5 | Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
| AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1 | High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
| AID1745845 | Primary qHTS for Inhibitors of ATXN expression | |||
| [information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||||
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 2 (13.33) | 18.7374 |
| 1990's | 3 (20.00) | 18.2507 |
| 2000's | 3 (20.00) | 29.6817 |
| 2010's | 5 (33.33) | 24.3611 |
| 2020's | 2 (13.33) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| This Compound (11.74) All Compounds (24.57) |
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 1 (6.25%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 15 (93.75%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||